Chi-Med's surufatinib now meets pancreatic neuroendocrine tumors endpoint

20 January 2020

Chinese company Hutchison China MediTech (AIM: HCM), a firm commonly-known as Chi-Med, has shown the potential of its wholly-owned asset surufatinib in another indication.

The Phase III pivotal study of surufatinib in advanced neuroendocrine tumors has been stopped early, the company has announced, as the pre-defined primary endpoint of progression free survival has already been met.

Following the early success of this study, Chi-Med now plans to arrange a pre-New Drug Application meeting with the China National Medical Products Administration to discuss the preparation of the NDA for surufatinib for this indication.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK